Recent Updates — LEXXW

Lexaria Bioscience Corp. received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2). As a result of this cure, the previously requested hearing regarding the deficiency was cancelled, and the company's Common Stock will continue to be listed on The Nasdaq Capital Market. Lexaria Bioscience Corp. operates in the biotechnology industry, focusing on the development of cannabis-based therapeutics.

Lexaria Bioscience Corp. filed a Certificate of Change with the State of Nevada to effect a 1-for-15 reverse stock split of its common stock. The transaction reduces authorized shares from 220,000,000 to 14,666,667 and outstanding shares from approximately 24,787,446 to roughly 1,652,518. The split becomes effective at 12:01 a.m. Eastern Time on August 3, 2026, with trading commencing on a split-adjusted basis that day. Fractional shares are rounded up to whole shares rather than paid out in cash. Management states the primary purpose is to regain compliance with NASDAQ Capital Market's minimum $1.00 bid price requirement and stabilize stock conditions to attract business partners. Lexaria Bioscience Corp. operates as a biotechnology company specializing in drug delivery platforms.